Products
Our pipeline: Delivering first-in-class immunotherapies of activation and regulation
Four clinical assets
- Immuno-Oncology
- Immuno-Inflammation
Product candidate
Indication (targets)
Research
IND-enabling
Phase 1
Phase 2
Phase 3
Significant partnerships with AbbVie, Boehringer Ingelheim, Veloxis Pharmaceuticals and CKD for up to €2.1 billion in milestones (€180 million already received)
Our portfolio of clinical assets and research platforms
In Immuno-Oncology and Immuno-Inflammation